The Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Cancer Institute (NCI) awarded a multiple-award indefinite delivery/indefinite quantity (IDIQ) contract to Weill Medical College of Cornell University to provide preclinical research services for the PREVENT Cancer Preclinical Drug Development Program. Under this $149,995,000 IDIQ, the contractor performs efficacy testing, biomarker evaluation, and analytical assay development to advance cancer preventive agents for clinical trials. The contract has three separate pools: the PREVENT Efficacy Pool, PREVENT CGMP Pool, and PREVENT Toxicology and Pharmacology Pool. Through task orders, NCI seeks support across these areas to establish a structured approach for transitioning cancer preventive drugs and vaccines from discovery to the clinic. Sample task orders include studies on the effect of a chemopreventive agent on the fecal metabolite profile in intestinal neoplasia, development of a polyvalent vaccine against fusion proteins observed in solid tumors, repurposing itraconazole for topical treatment of basal cell carcinoma, and evaluating blood-based biomarkers of obesity-induced breast inflammation. Weill Medical College, a private non-profit research university, performs this work at its facilities in New York.
Generated 5/1/24, 9:16 AM